Targeting HER2 in ovarian and uterine cancers: Challenges and future directions

Gynecologic Oncology

Volumn 135, Issue 2, 2014, Pages 364-370

  Teplinsky, Eleonora ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Endometrial cancer; HER2; Ovarian cancer; Targeted therapy; Trastuzumab; Uterine cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; LAPATINIB; MAYTANSINE; MONOCLONAL ANTIBODY; PERTUZUMAB; QUINAZOLINE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ARTICLE; CANCER PROGNOSIS; COLLOID CARCINOMA; HUMAN; OVARY CANCER; OVARY CARCINOMA; UTERINE SEROUS CARCINOMA; UTERUS CANCER; UTERUS CARCINOMA; ADENOCARCINOMA, MUCINOUS; ANALOGS AND DERIVATIVES; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; GENETICS; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PROTO ONCOGENE; UTERINE NEOPLASMS;

ADENOCARCINOMA, MUCINOUS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; MAYTANSINE; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; QUINAZOLINES; UTERINE NEOPLASMS;

EID: 84913621210     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.09.003     Document Type: Review

References (70)

1. S.O. Joseph, J. Wu, and F.M. Muggia Targeted therapy: its status and promise in selected solid tumors. Part II: Impact on selected tumor subsets, and areas of evolving integration Oncology 26 11 2012 1021 1030 1035
2. D.P. English, D.M. Roque, and A.D. Santin HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies Mol Diagn Ther 17 2 2013 85 99
3. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, and D.E. Keith Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 4905 1989 707 712
4. D. Jelovac, and L.A. Emens HER2-directed therapy for metastatic breast cancer Oncology 27 3 2013 166 175
5. Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, and A. Sawaki Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 9742 2010 687 697
6. K. Jhaveri, and F.J. Esteva Pertuzumab in the treatment of HER2 + breast cancer J Natl Compr Canc Netw 12 4 2014 591 598
7. M.C. de Toledo, L.O. Sarian, L.F. Sallum, L.L. Andrade, J. Vassallo, and G.R. de Paiva Silva Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer Acta Histochem 116 3 2014 440 447
8. J. Reibenwein, and M. Krainer Targeting signaling pathways in ovarian cancer Expert Opin Ther Targets 12 3 2008 353 365
9. A. Serrano-Olvera, A. Duenas-Gonzalez, D. Gallardo-Rincon, M. Candelaria, and J. De la Garza-Salazar Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer Cancer Treat Rev 32 3 2006 180 190
10. E. Lanitis, D. Dangaj, I.S. Hagemann, D.G. Song, A. Best, and R. Sandaltzopoulos Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels PLoS One 7 11 2012 e49829
11. D.P. Wang, I. Konishi, M. Koshiyama, Y. Nanbu, T. Iwai, and H. Nonogaki Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary Virchows Arch A Pathol Anat Histopathol 421 5 1992 393 400
12. I. Hellstrom, G. Goodman, J. Pullman, Y. Yang, and K.E. Hellstrom Overexpression of HER-2 in ovarian carcinomas Cancer Res 61 6 2001 2420 2423
13. A. Choudhury, J. Charo, S.K. Parapuram, R.C. Hunt, D.M. Hunt, and B. Seliger Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines Int J Cancer 108 1 2004 71 77
14. N. Tsuda, K. Kawano, C.L. Efferson, and C.G. Ioannides Synthetic microRNA and double-stranded RNA targeting the 3'-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells Int J Oncol 27 5 2005 1299 1306
15. J.P. Delord, C. Allal, M. Canal, E. Mery, P. Rochaix, and I. Hennebelle Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma Ann Oncol 16 12 2005 1889 1897
16. B. Tanner, D. Hasenclever, K. Stern, W. Schormann, M. Bezler, and M. Hermes ErbB-3 predicts survival in ovarian cancer J Clin Oncol 24 26 2006 4317 4323
17. P.J. Frederick, J.M. Straughn Jr., R.D. Alvarez, and D.J. Buchsbaum Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer Gynecol Oncol 113 3 2009 384 390
18. P. Mullen, D.A. Cameron, M. Hasmann, J.F. Smyth, and S.P. Langdon Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling Mol Cancer Ther 6 1 2007 93 100
19. A.H. Sims, A.J. Zweemer, Y. Nagumo, D. Faratian, M. Muir, and M. Dodds Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer Br J Cancer 106 11 2012 1779 1789
20. A. Aigner, S.S. Hsieh, C. Malerczyk, and F. Czubayko Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol Toxicology 144 1-3 2000 221 228
21. S. Abuharbeid, J. Apel, G. Zugmaier, C. Knabbe, M. Sander, and S. Gilbert Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells Naunyn Schmiedebergs Arch Pharmacol 371 2 2005 141 151
22. M.R. Raspollini, G. Amunni, A. Villanucci, F. Castiglione, D. Rossi Degl'Innocenti, and G. Baroni HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival Appl Immunohistochem Mol Morphol 14 2 2006 181 186
23. M. Tuefferd, J. Couturier, F. Penault-Llorca, A. Vincent-Salomon, P. Broet, and J.P. Guastalla HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients PLoS One 2 11 2007 e1138
24. H. Lassus, A. Leminen, A. Vayrynen, G. Cheng, J.A. Gustafsson, and J. Isola ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma Gynecol Oncol 92 1 2004 31 39
25. E. Verri, P. Guglielmini, M. Puntoni, L. Perdelli, A. Papadia, and P. Lorenzi HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance Clin Study Oncol 68 2-3 2005 154 161
26. J.S. Nielsen, E. Jakobsen, B. Holund, K. Bertelsen, and A. Jakobsen Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer Int J Gynecol Cancer 14 6 2004 1086 1096
27. D. Zhao, F. Zhang, W. Zhang, J. He, Y. Zhao, and J. Sun Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis Int J Gynecol Cancer 23 1 2013 25 33
28. W.Y. Chay, S.H. Chew, W.S. Ong, I. Busmanis, X. Li, and S. Thung HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer PLoS One 8 4 2013 e61565
29. M.S. Anglesio, S. Kommoss, M.C. Tolcher, B. Clarke, L. Galletta, and H. Porter Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas J Pathol 229 1 2013 111 120
30. B. Yan, S.N. Choo, P. Mulyadi, S. Srivastava, C.W. Ong, and K.J. Yong Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours J Clin Pathol 64 12 2011 1097 1101
31. J.N. McAlpine, K.C. Wiegand, R. Vang, B.M. Ronnett, A. Adamiak, and M. Kobel HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy BMC Cancer 9 2009 433
32. H. McCaughan, I. Um, S.P. Langdon, D.J. Harrison, and D. Faratian HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis J Clin Pathol 65 7 2012 670 671 [author reply 1-2]
33. M.A. Bookman, K.M. Darcy, D. Clarke-Pearson, R.A. Boothby, and I.R. Horowitz Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group J Clin Oncol 21 2 2003 283 290
34. M.S. Gordon, D. Matei, C. Aghajanian, U.A. Matulonis, M. Brewer, and G.F. Fleming Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status J Clin Oncol 24 26 2006 4324 4332
35. S. Makhija, L.C. Amler, D. Glenn, F.R. Ueland, M.A. Gold, and D.S. Dizon Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer J Clin Oncol 28 7 2010 1215 1223
36. S.B. Kaye, C.J. Poole, A. Danska-Bidzinska, L. Gianni, G. Del Conte, and V. Gorbunova A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer Ann Oncol 24 1 2013 145 152
37. M.C. Rivkin SE, D. Iriarte, J. Arthur, A. Canoy, and H. Reid Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients J Clin Oncol 26 15S (May 20 Supplement) 2008 5556
38. S. Lheureux, S. Krieger, B. Weber, P. Pautier, M. Fabbro, and F. Selle Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial Int J Gynecol Cancer 22 9 2012 1483 1488
39. A.A. Garcia, M.W. Sill, H.A. Lankes, A.K. Godwin, R.S. Mannel, and D.K. Armstrong A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 124 3 2012 569 574
40. A. Berchuck, G. Rodriguez, R.B. Kinney, J.T. Soper, R.K. Dodge, and D.L. Clarke-Pearson Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease Am J Obstet Gynecol 164 1 Pt 1 1991 15 21
41. C. Morrison, V. Zanagnolo, N. Ramirez, D.E. Cohn, N. Kelbick, and L. Copeland HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients J Clin Oncol 24 15 2006 2376 2385
42. G.E. Konecny, N. Venkatesan, G. Yang, J. Dering, C. Ginther, and R. Finn Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells Br J Cancer 98 6 2008 1076 1084
43. G.E. Konecny, L. Santos, B. Winterhoff, M. Hatmal, G.L. Keeney, and A. Mariani HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer Br J Cancer 100 1 2009 89 95
44. G. Peiro, D. Mayr, P. Hillemanns, U. Lohrs, and J. Diebold Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome Mod Pathol 17 3 2004 227 287
45. D. Chakravarty, N. Gupta, J.S. Goda, R. Srinivasan, F.D. Patel, and L. Dhaliwal Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: correlation with conventional histomorphological features of prognosis Acta Histochem 112 4 2010 355 363
46. Cancer Genome Atlas Research N, C. Kandoth, N. Schultz, A.D. Cherniack, R. Akbani, and Y. Liu Integrated genomic characterization of endometrial carcinoma Nature 497 7447 2013 67 73
47. A.D. Santin, S. Bellone, E.R. Siegel, M. Palmieri, M. Thomas, and M.J. Cannon Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer Am J Obstet Gynecol 192 3 2005 813 818
48. T.A. Grushko, V.L. Filiaci, A.J. Mundt, K. Ridderstrale, O.I. Olopade, and G.F. Fleming An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 108 1 2008 3 9
49. C.E. Cross SN, S. Bellone, V.K. Anagnostou, S.L. Brower, C.E. Richter, and E.R. Siegel Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro Am J Obstet Gynecol 203 2 2010 162.e1-8
50. A.D. Santin, S. Bellone, M. Gokden, M. Palmieri, D. Dunn, and J. Agha Overexpression of HER-2/neu in uterine serous papillary cancer Clin Cancer Res 8 5 2002 1271 1279
51. B.M. Slomovitz, R.R. Broaddus, T.W. Burke, N. Sneige, P.T. Soliman, and W. Wu Her-2/neu overexpression and amplification in uterine papillary serous carcinoma J Clin Oncol 22 15 2004 3126 3132
52. P. Todeschini, E. Cocco, S. Bellone, J. Varughese, K. Lin, and L. Carrara Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab Br J Cancer 105 8 2011 1176 1182
53. A.N. Fader, A.D. Santin, and P.A. Gehrig Early stage uterine serous carcinoma: management updates and genomic advances Gynecol Oncol 129 1 2013 244 250
54. A.D. Santin, S. Bellone, S. Van Stedum, W. Bushen, M. Palmieri, and E.R. Siegel Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma Cancer 104 7 2005 1391 1397
55. T.P. Diaz-Montes, H. Ji, A.E. Smith Sehdev, M.L. Zahurak, R.J. Kurman, and D.K. Armstrong Clinical significance of Her-2/neu overexpression in uterine serous carcinoma Gynecol Oncol 100 1 2006 139 144
56. D.J. Hetzel, T.O. Wilson, G.L. Keeney, P.C. Roche, S.S. Cha, and K.C. Podratz HER-2/neu expression: a major prognostic factor in endometrial cancer Gynecol Oncol 47 2 1992 179 185
57. A.D. Santin, S. Bellone, J.J. Roman, J.K. McKenney, and S. Pecorelli Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu Int J Gynaecol Obstet 102 2 2008 128 131
58. E. Jewell, A.A. Secord, T. Brotherton, and A. Berchuck Use of trastuzumab in the treatment of metastatic endometrial cancer Int J Gynecol Cancer 16 3 2006 1370 1373
59. J.A. Villella, S. Cohen, D.H. Smith, H. Hibshoosh, and D. Hershman HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications Int J Gynecol Cancer 16 5 2006 1897 1902
60. G.F. Fleming, M.W. Sill, K.M. Darcy, D.S. McMeekin, J.T. Thigpen, and L.M. Adler Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 116 1 2010 15 20
61. K.K. Leslie, M.W. Sill, H.A. Lankes, E.G. Fischer, A.K. Godwin, and H. Gray Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer Gynecol Oncol 127 2 2012 345 350
62. Clinicaltrials.gov Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer (NCT01367002) [cited 2013 December 25, 2013]. Available from: http://clinicaltrials.gov/ct2/show/NCT01367002?term=NCT01367002&rank=1 2013
63. R. Nahta, and F.J. Esteva HER2 therapy: molecular mechanisms of trastuzumab resistance Breast Cancer Res 8 6 2006 215
64. M.P. Ponnusamy, P. Seshacharyulu, A. Vaz, P. Dey, and S.K. Batra MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells J Ovarian Res 4 1 2011 7
65. M.P. Ponnusamy, A.P. Singh, M. Jain, S. Chakraborty, N. Moniaux, and S.K. Batra MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells Br J Cancer 99 3 2008 520 526
66. W.L. Lin, W.H. Kuo, F.L. Chen, M.Y. Lee, A. Ruan, and Y.S. Tyan Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer Ann Surg Oncol 18 8 2011 2388 2394
67. H. Lassus, H. Sihto, A. Leminen, H. Joensuu, J. Isola, and N.N. Nupponen Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma J Mol Med 84 8 2006 671 681
68. Clinicaltrials.gov An Open-label, Phase 2 Study of Neratinib in HER2 (ERBB2) Mutation Positive Solid Tumor Patients (NCT01953926) 2013
69. B.M. Slomovitz, and R.L. Coleman The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer Clin Cancer Res 18 21 2012 5856 5864
70. F. Andre, R. O'Regan, M. Ozguroglu, M. Toi, B. Xu, and G. Jerusalem Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial Lancet Oncol 15 6 2014 580 591